Georg Lübben Selected Research

Type 2 Diabetes Mellitus (MODY)

06/2007	Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus.
01/2007	Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus.
01/2006	Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus.
01/2005	Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
01/2005	Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study.
06/2004	A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
01/2004	Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
01/2003	Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus.
01/2003	Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice.

6	pioglitazone (Actos)FDA Link 06/2008 - 01/2003
4	ProinsulinIBA 04/2007 - 03/2004
2	RelaxinIBA 06/2007 - 01/2007
2	Insulin (Novolin)FDA Link 04/2007 - 01/2003
2	AdiponectinIBA 04/2007 - 12/2004
1	Fibrinogen (Factor I)IBA 06/2007
1	Simvastatin (Zocor)FDA LinkGeneric 04/2007
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2007
1	C-Reactive ProteinIBA 01/2006
1	Glucose (Dextrose)FDA LinkGeneric 10/2005
1	2,4-thiazolidinedione (thiazolidinedione)IBA 01/2005
1	ThiazolidinedionesIBA 06/2004
1	Metformin (Glucophage)FDA LinkGeneric 06/2004